Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Apply
Amivantamab & Pembrolizumab
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step